Today's Information |
Provided by: TaiMed Biologics Inc. | |||||
SEQ_NO | 1 | Date of announcement | 2022/04/20 | Time of announcement | 20:45:42 |
Subject | The US FDA completed a pre-approval inspection (PAI) of TaiMed cGMP monoclonal antibody facility with no observation | ||||
Date of events | 2022/04/20 | To which item it meets | paragraph 53 | ||
Statement | 1.Date of occurrence of the event:2022/04/20 2.Company name:TaiMed Biologics Inc. 3.Relationship to the Company (please enter "head office" or "subsidiaries"):Head Office 4.Reciprocal shareholding ratios:N/A 5.Cause of occurrence: The US FDA completed a pre-approval inspection (PAI) of TaiMed Biologics' brand new cGMP monoclonal antibody facility on April 20th, 2022. There is no 483 observation (inspectional observation). The positive outcome adds further assurance for its newly-established Contract Development and Manufacturing (CDMO) business. 6.Countermeasures:None 7.Any other matters that need to be specified: New drug development requires a long process and sizeable investments with no guarantee of success, which therefore may pose substantial investment risks. Investors are advised to exercise caution and conduct thorough evaluation. |
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
TaiMed Biologics Inc. published this content on 20 April 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 20 April 2022 12:54:10 UTC.